The i-Thymus: wielding the potential of gene therapy, cell therapy and induced p...
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system
Each year, >250 babies are born without a thymus. These babies have a life expectancy of 2-3 years. The only cure is transplantation of thymus tissue, but this has a 30% mortality rate and costs almost >€2.5M. We developed i-Thymu...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RESHAPE
Reshaping undesired Inflammation in challenged Tissue Homeos...
13M€
Cerrado
THYMISTEM
Development of Stem Cell Based Therapy for Thymic Regenerati...
8M€
Cerrado
REGENERATIVETHERAPY
Cell and gene therapy approaches for inherited diseases with...
2M€
Cerrado
PID2020-116352GB-I00
INTERACCION DE LAS CELULAS MADRE PLURIPOTENTES INDUCIDAS (IP...
230K€
Cerrado
SAF2014-62233-EXP
EXPLORANDO UNA ESTRATEGIA DE REJUVENECIMIENTO DEL SISTEMA IN...
85K€
Cerrado
Información proyecto i-THYMUS
Duración del proyecto: 23 meses
Fecha Inicio: 2023-11-17
Fecha Fin: 2025-10-31
Líder del proyecto
GENEWITY BV
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Each year, >250 babies are born without a thymus. These babies have a life expectancy of 2-3 years. The only cure is transplantation of thymus tissue, but this has a 30% mortality rate and costs almost >€2.5M. We developed i-Thymus, a revolutionary cure based on the patient’s own cells leveraging innovative gene therapy to generate thymus organoids that can be implanted minimally invasively in the patient (Fig. 1). We have already shown this works in functional proof of concept in vivo. With this EIC Accelerator, we will finalise development to enter the clinic for a Phase I/II trial, to enter the EU market with a pharma partner by 2028. After rapid market entry with ODD for complete DiGeorge syndrome, we will leverage this clinical success and our first revenues to develop i-Thymus for unmet needs of hundreds of thousands of other patients, starting with AML patients who have lost thymus function after high-dose chemotherapy for stem cell transplantation.